Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Melnikova, Vladislava
Vibat, Cecile Rose T.
Ning, Van
Agafitei, Raluca Dana
Hanna, Diana L.
Hancock, Saege
Erlander, Mark G.
Lenz, Heinz-Josef
Barzi, Afsaneh
机构：
[1] Trovagene Inc, San Diego, CA USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Southern Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15011
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] The prevalence of common KRAS variants and associated outcomes in patients with metastatic colorectal cancer (mCRC)
    Musselwhite, Laura W.
    Trufan, Sally J.
    Kadakia, Kunal C.
    Hwang, Jimmy J.
    Salem, Mohamed E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).
    Vincenzi, Bruno
    Loupakis, Fotios
    Bianchi, Andrea Sartore
    Russo, Antonio
    Mannavola, Francesco
    Perrone, Giuseppe
    Cremolini, Chiara
    Rossini, Daniele
    Ongaro, Elena
    Bonazzina, Erica
    Dell'Aquila, Emanuela
    Imperatori, Marco
    De Maglio, Giovanna
    Falcone, Alfredo
    Santini, Daniele
    Onetti-Muda, Andrea
    Siena, Salvatore
    Aprile, Giuseppe
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Predictors of treatment attrition in patients with metastatic colorectal cancer (mCRC).
    Bahrabadi, Arvin
    Ruan, Jenny
    Gresham, Gillian
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Treatment and survival of patients with de novo metastatic colorectal cancer (mCRC) rested for KRAS, NRAS or BRAF mutations
    Booker, Ben D.
    Markt, Sarah C.
    Schumacher, Fredrick R.
    Rose, Johnie
    Cooper, Greg S.
    Selfridge, J. Eva
    Koroukian, Siran M.
    CANCER RESEARCH, 2022, 82 (12)
  • [6] BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts)
    Bergamo, Francesca
    Schirripa, Marta
    Loupakis, Fotios
    Cremolini, Chiara
    Casagrande, Mariaelena
    Lonardi, Sara
    Aprile, Giuseppe
    Marmorino, Federica
    Salvatore, Lisa
    Antoniotti, Carlotta
    Sensi, Elisa
    Lupi, Cristiana
    De Maglio, Giovanna
    Bertorelle, Roberta
    Galiano, Antonella
    Griguolo, Gaia
    Balistreri, Mariangela
    Fontanini, Gabriella
    Zagonel, Vittorina
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Treatment of elderly patients with metastatic colorectal cancer (MCRC): Our experience
    Longo, F.
    Proietti, E.
    Raimondi, C.
    Graziano, V
    Zivi, A.
    Sacco, P.
    Cerbone, I
    Russillo, M.
    Restuccia, M.
    di Seri, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 74 - 74
  • [8] Comorbidities in patients with metastatic colorectal cancer (mCRC)
    Fu, A. Z.
    Zhao, Z.
    Wang, P. F.
    Barber, B.
    Liu, G. G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [9] Treatment patterns and site of metastasis in patients with metastatic colorectal cancer (mCRC)
    Iqbal, Sheikh Usman
    Thompson, Stephen F.
    Naoshy, Sarah
    Ng, Daniel B.
    Wooten, Michael
    Sherman, Steven A.
    Malangone, Elisabetta
    Stern, Lee
    Gorritz-Kindu, Magdaliz
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Metastatic colorectal Cancer (mCRC) New Treatment Option for pretreated Patients
    Arnold, Dirk
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (09) : 577 - 577
12345